Literature DB >> 24578126

The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.

Jeffrey J Talbot1, Xuewen Song2, Xiaofang Wang3, Markus M Rinschen4, Nicholas Doerr1, Wells B LaRiviere3, Bernhard Schermer5, York P Pei2, Vicente E Torres3, Thomas Weimbs6.   

Abstract

Polycystin-1 (PC1) mutations result in proliferative renal cyst growth and progression to renal failure in autosomal dominant polycystic kidney disease (ADPKD). The transcription factor STAT3 (signal transducer and activator of transcription 3) was shown to be activated in cyst-lining cells in ADPKD and PKD mouse models and may drive renal cyst growth, but the mechanisms leading to persistent STAT3 activation are unknown. A proteolytic fragment of PC1 corresponding to the cytoplasmic tail, PC1-p30, is overexpressed in ADPKD. Here, we show that PC1-p30 interacts with the nonreceptor tyrosine kinase Src, resulting in Src-dependent activation of STAT3 by tyrosine phosphorylation. The PC1-p30-mediated activation of Src/STAT3 was independent of JAK family kinases and insensitive to the STAT3 inhibitor suppressor of cytokine signaling 3. Signaling by the EGF receptor (EGFR) or cAMP amplified the activation of Src/STAT3 by PC1-p30. Expression of PC1-p30 changed the cellular response to cAMP signaling. In the absence of PC1-p30, cAMP dampened EGFR- or IL-6-dependent activation of STAT3; in the presence of PC1-p30, cAMP amplified Src-dependent activation of STAT3. In the polycystic kidney (PCK) rat model, activation of STAT3 in renal cystic cells depended on vasopressin receptor 2 (V2R) signaling, which increased cAMP levels. Genetic inhibition of vasopressin expression or treatment with a pharmacologic V2R inhibitor strongly suppressed STAT3 activation and reduced renal cyst growth. These results suggest that PC1, via its cleaved cytoplasmic tail, integrates signaling inputs from EGFR and cAMP, resulting in Src-dependent activation of STAT3 and a proliferative response.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24578126      PMCID: PMC4116067          DOI: 10.1681/ASN.2013091026

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  74 in total

1.  Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.

Authors:  Wouter N Leonhard; Annemieke van der Wal; Zlata Novalic; Steven J Kunnen; Ron T Gansevoort; Martijn H Breuning; Emile de Heer; Dorien J M Peters
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-23

2.  ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases.

Authors:  M A Olayioye; I Beuvink; K Horsch; J M Daly; N E Hynes
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

3.  Suppressors of cytokine signaling abrogate diabetic nephropathy.

Authors:  Guadalupe Ortiz-Muñoz; Virginia Lopez-Parra; Oscar Lopez-Franco; Paula Fernandez-Vizarra; Beñat Mallavia; Claudio Flores; Ana Sanz; Julia Blanco; Sergio Mezzano; Alberto Ortiz; Jesus Egido; Carmen Gomez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 10.121

Review 4.  Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD).

Authors:  William E Sweeney; Ellis D Avner
Journal:  Cell Tissue Res       Date:  2006-06-10       Impact factor: 5.249

Review 5.  Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1.

Authors:  Thomas Weimbs
Journal:  Am J Physiol Renal Physiol       Date:  2007-08-22

Review 6.  Feedback inhibitors of the epidermal growth factor receptor signaling pathways.

Authors:  Noriko Gotoh
Journal:  Int J Biochem Cell Biol       Date:  2008-08-09       Impact factor: 5.085

7.  Vasopressin directly regulates cyst growth in polycystic kidney disease.

Authors:  Xiaofang Wang; Yanhong Wu; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

8.  STAT3 Signaling in Polycystic Kidney Disease.

Authors:  Thomas Weimbs; Jeffrey J Talbot
Journal:  Drug Discov Today Dis Mech       Date:  2013-12-01

9.  Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury.

Authors:  Sony Prasad; John Patrick McDaid; Frederick Wai Keung Tam; John Lionel Haylor; Albert Chee Meng Ong
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

10.  Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms.

Authors:  Kohjiro Ueki; Tatsuya Kondo; C Ronald Kahn
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more
  31 in total

Review 1.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 2.  Src family kinases in chronic kidney disease.

Authors:  Jun Wang; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2017-06-14

3.  Polycystin-1 regulates bone development through an interaction with the transcriptional coactivator TAZ.

Authors:  David Merrick; Kavita Mistry; Jingshing Wu; Nikolay Gresko; Julie E Baggs; John B Hogenesch; Zhaoxia Sun; Michael J Caplan
Journal:  Hum Mol Genet       Date:  2019-01-01       Impact factor: 6.150

4.  Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Authors:  Jacob A Torres; Mina Rezaei; Caroline Broderick; Louis Lin; Xiaofang Wang; Bernd Hoppe; Benjamin D Cowley; Vincenzo Savica; Vicente E Torres; Saeed Khan; Ross P Holmes; Michal Mrug; Thomas Weimbs
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

5.  Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis.

Authors:  Zhousheng Xiao; Jerome Baudry; Li Cao; Jinsong Huang; Hao Chen; Charles R Yates; Wei Li; Brittany Dong; Christopher M Waters; Jeremy C Smith; L Darryl Quarles
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

6.  SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC.

Authors:  Sulin Zhang; Zhiwen Yang; Weilian Bao; Lixin Liu; Yan You; Xu Wang; Liming Shao; Wei Fu; Xinhui Kou; Weixing Shen; Congmin Yuan; Bin Hu; Wenzhen Dang; Kutty Selva Nandakumar; Hualiang Jiang; Mingyue Zheng; Xiaoyan Shen
Journal:  Autophagy       Date:  2019-07-04       Impact factor: 16.016

7.  N-Degradomic Analysis Reveals a Proteolytic Network Processing the Podocyte Cytoskeleton.

Authors:  Markus M Rinschen; Ann-Kathrin Hoppe; Florian Grahammer; Martin Kann; Linus A Völker; Eva-Maria Schurek; Julie Binz; Martin Höhne; Fatih Demir; Milena Malisic; Tobias B Huber; Christine Kurschat; Jayachandran N Kizhakkedathu; Bernhard Schermer; Pitter F Huesgen; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2017-07-19       Impact factor: 10.121

8.  Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.

Authors:  Jacob A Torres; Samantha L Kruger; Caroline Broderick; Tselmeg Amarlkhagva; Shagun Agrawal; John R Dodam; Michal Mrug; Leslie A Lyons; Thomas Weimbs
Journal:  Cell Metab       Date:  2019-10-17       Impact factor: 27.287

Review 9.  Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

Authors:  Wells B LaRiviere; Maria V Irazabal; Vicente E Torres
Journal:  Transl Res       Date:  2014-11-13       Impact factor: 7.012

Review 10.  A cut above (and below): Protein cleavage in the regulation of polycystin trafficking and signaling.

Authors:  Valeria Padovano; Kavita Mistry; David Merrick; Nikolay Gresko; Michael J Caplan
Journal:  Cell Signal       Date:  2020-04-10       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.